Who does semaglutide not work for — and when it may not be the right choice

Step 1: The groups for whom semaglutide is not licensed or recommended at all

Before asking whether semaglutide will work, the prior question is whether it is safe to take. Under the Wegovy SmPC and NHS guidance, several groups are excluded entirely.

Pregnancy comes first. Semaglutide is not recommended during pregnancy, and anyone trying to conceive should stop treatment and allow a wash-out period beforehand, the MHRA advises using effective contraception throughout treatment. Breastfeeding is also an exclusion: it is not known whether the medicine passes into breast milk. These are not precautionary grey areas; they are firm clinical positions documented in the NHS patient guide to semaglutide.

Under-18s sit in the same category. Wegovy for weight management has no licence for anyone below 18 in the UK. Age alone is enough for a prescriber to decline.

Two medical histories trigger an absolute caution: medullary thyroid carcinoma (a specific thyroid cancer) and Multiple Endocrine Neoplasia type 2. Animal studies flagged thyroid-cell changes with GLP-1 medicines, and although the human relevance remains uncertain, the precautionary position is clear, anyone with a personal or family history of either condition is not a candidate. A prescriber will ask about this directly.

Severe gastrointestinal disease, including conditions affecting gastric motility, also warrants careful assessment; slowing gastric emptying further in someone whose gut is already compromised can worsen their situation significantly. Pancreatitis history adds another flag. The MHRA issued specific guidance on GLP-1 medicines and pancreatitis risk in January 2026, reinforcing that this history must be declared and assessed before any prescription is written.

Step 2: The people semaglutide is not contraindicated for, but may not work well in

A different, and perhaps more practically useful, group are those who are technically eligible but for whom semaglutide is less likely to produce the results they hope for.

Diet and activity matter far more than the adverts suggest. Semaglutide reduces appetite and slows gastric emptying (the mechanism is well-understood) but it does not remove the need for a calorie deficit. Someone who compensates for reduced hunger by choosing higher-calorie foods in smaller quantities will see substantially less benefit. Clinical trials in which participants combined semaglutide with structured dietary support produced the headline 15% average weight-loss figures; real-world results vary.

People with certain metabolic conditions, including hypothyroidism that is not well-controlled, may find weight loss slower or more modest. Hypothyroidism does not disqualify someone from treatment, but it is a variable that a prescriber factors into expectations. Similarly, some medicines taken alongside semaglutide can reduce its effectiveness, not through a direct pharmacokinetic clash, but through effects on appetite, fluid retention, or metabolism. Corticosteroids are a common example, and if fluid retention is a concern for you, it is worth reading about whether Wegovy helps with water retention before drawing conclusions about your progress.

Rare but documented: a small proportion of people appear to be low or non-responders to GLP-1 medicines even when adherent and on the full maintenance dose. NICE guidance for semaglutide (TA875) notes that if weight loss is under 5% after six months on the maintenance dose, continuing should be reviewed. This is not a failure of the patient; it reflects genuine biological variation in GLP-1 receptor response. If that applies to you, there is more detail on why Wegovy sometimes underperforms.

Step 3: Situations where semaglutide is the wrong medicine at the wrong time

Timing and circumstances matter, too. Three situations recur in clinical practice.

Surgery is one. If you are scheduled for a procedure under general anaesthetic, your prescribing team and anaesthetist need to know you are taking semaglutide, it slows gastric emptying and can increase the risk of aspiration during anaesthesia. NHS England's guidance on weight-management injections is explicit on this point, and a responsible prescriber will discuss it at review.

Oral contraceptives present a specific consideration for tirzepatide rather than semaglutide, but it is worth noting for anyone considering switching between the two medicines. For semaglutide, there is no established evidence of reduced pill absorption, though it is always worth raising any hormonal medicine with your prescriber at review. Some people also notice changes in their sleep patterns during treatment, and if that is something you are experiencing, there is useful reading on whether Wegovy has any effect on sleep quality.

Finally, motivation and readiness. Semaglutide demands some consistency: the weekly injection schedule, the dietary changes, the regular clinical reviews. Someone who travels frequently and cannot store the pen refrigerated reliably, or who finds injections distressing, may be better placed to discuss alternatives, including oral semaglutide, approved by the MHRA in June 2026 as the UK's first GLP-1 tablet for weight management. Room-temperature storage makes it considerably more practical for some people.

The treatment options at nume are reviewed at consultation so that the prescriber can match the right medicine to the right person, rather than defaulting to the most-searched one. That review covers your medical history, your current medicines, your circumstances, and your goals, done the same day by a real clinician, not software. It is also worth reading about the reasons Wegovy may underperform before starting, so your expectations are grounded in evidence. For a broader look at the treatment landscape, our weight-loss overview sets out what is currently available through a UK-regulated pharmacy.

According to NICE's appraisal of semaglutide (TA875), the medicine is recommended within a specialist weight management service and for a maximum of two years, context that shapes whether it is the right long-term approach for your situation. A prescriber can talk through what that means in practice.